270 related articles for article (PubMed ID: 31667578)
1. Altered serum level of metabolic and endothelial factors in patients with systemic sclerosis.
Stochmal A; Czuwara J; Zaremba M; Rudnicka L
Arch Dermatol Res; 2020 Aug; 312(6):453-458. PubMed ID: 31667578
[TBL] [Abstract][Full Text] [Related]
2. Metabolic mediators determine the association of antinuclear antibody subtypes with specific clinical symptoms in systemic sclerosis.
Stochmal A; Czuwara J; Zaremba M; Rudnicka L
Adv Med Sci; 2021 Mar; 66(1):119-127. PubMed ID: 33494024
[TBL] [Abstract][Full Text] [Related]
3. Increased serum levels of fractalkine and mobilisation of CD34
Benyamine A; Magalon J; Cointe S; Lacroix R; Arnaud L; Bardin N; Rossi P; Francès Y; Bernard-Guervilly F; Kaplanski G; Harlé JR; Weiller PJ; Berbis P; Braunstein D; Jouve E; Lesavre N; Couranjou F; Dignat-George F; Sabatier F; Paul P; Granel B
Arthritis Res Ther; 2017 Mar; 19(1):60. PubMed ID: 28320472
[TBL] [Abstract][Full Text] [Related]
4. The role of adipokines in systemic sclerosis: a missing link?
Żółkiewicz J; Stochmal A; Rudnicka L
Arch Dermatol Res; 2019 May; 311(4):251-263. PubMed ID: 30806766
[TBL] [Abstract][Full Text] [Related]
5. Epoprostenol up-regulates serum adiponectin level in patients with systemic sclerosis: therapeutic implications.
Stochmal A; Czuwara J; Zaremba M; Rudnicka L
Arch Dermatol Res; 2021 Nov; 313(9):783-791. PubMed ID: 33433715
[TBL] [Abstract][Full Text] [Related]
6. Circulating adipokines and organ involvement in patients with systemic sclerosis.
Olewicz-Gawlik A; Danczak-Pazdrowska A; Kuznar-Kaminska B; Batura-Gabryel H; Katulska K; Wojciech S; Trzybulska D; Hrycaj P
Acta Reumatol Port; 2015; 40(2):156-62. PubMed ID: 26219969
[TBL] [Abstract][Full Text] [Related]
7. Serum levels of galectin-3: possible association with fibrosis, aberrant angiogenesis, and immune activation in patients with systemic sclerosis.
Taniguchi T; Asano Y; Akamata K; Noda S; Masui Y; Yamada D; Takahashi T; Ichimura Y; Toyama T; Tamaki Z; Tada Y; Sugaya M; Kadono T; Sato S
J Rheumatol; 2012 Mar; 39(3):539-44. PubMed ID: 22247367
[TBL] [Abstract][Full Text] [Related]
8. Serum resistin levels: a possible correlation with pulmonary vascular involvement in patients with systemic sclerosis.
Masui Y; Asano Y; Akamata K; Aozasa N; Noda S; Taniguchi T; Takahashi T; Ichimura Y; Toyama T; Sumida H; Kuwano Y; Yanaba K; Tada Y; Sugaya M; Sato S; Kadono T
Rheumatol Int; 2014 Aug; 34(8):1165-70. PubMed ID: 24141536
[TBL] [Abstract][Full Text] [Related]
9. Adipokine expression in systemic sclerosis lung and gastrointestinal organ involvement.
Neumann E; Lepper N; Vasile M; Riccieri V; Peters M; Meier F; Hülser ML; Distler O; Gay S; Mahavadi P; Günther A; Roeb E; Frommer KW; Diller M; Müller-Ladner U
Cytokine; 2019 May; 117():41-49. PubMed ID: 30784899
[TBL] [Abstract][Full Text] [Related]
10. Serum leptin, resistin and TNF-α levels in patients with systemic sclerosis: the role of adipokines in scleroderma.
Pehlivan Y; Onat AM; Ceylan N; Turkbeyler IH; Buyukhatipoglu H; Comez G; Babacan T; Tarakcioglu M
Int J Rheum Dis; 2012 Aug; 15(4):374-9. PubMed ID: 22898217
[TBL] [Abstract][Full Text] [Related]
11. Meta-analysis of circulating adiponectin, leptin, and resistin levels in systemic sclerosis.
Lee YH; Song GG
Z Rheumatol; 2017 Nov; 76(9):789-797. PubMed ID: 27515182
[TBL] [Abstract][Full Text] [Related]
12. Increased serum fractalkine in systemic sclerosis. Down-regulation by prostaglandin E1.
Sicinska J; Gorska E; Cicha M; Kuklo-Kowalska A; Hamze V; Stepien K; Wasik M; Rudnicka L
Clin Exp Rheumatol; 2008; 26(4):527-33. PubMed ID: 18799080
[TBL] [Abstract][Full Text] [Related]
13. [Systemic sclerosis and scleroderma circumscripta--disturbances of selected serum parameters which are responsible for vascular changes and CD34 expression in involved skin].
Dziankowska-Bartkowiak B; Zebrowska A; Wagrowska-Danielewicz M; Kobos J; Waszczykowska E
Przegl Lek; 2009; 66(12):1040-5. PubMed ID: 20514902
[TBL] [Abstract][Full Text] [Related]
14. A potential contribution of decreased galectin-7 expression in stratified epithelia to the development of cutaneous and oesophageal manifestations in systemic sclerosis.
Saigusa R; Yamashita T; Miura S; Hirabayashi M; Nakamura K; Miyagawa T; Fukui Y; Yoshizaki A; Sato S; Asano Y
Exp Dermatol; 2019 May; 28(5):536-542. PubMed ID: 30739341
[TBL] [Abstract][Full Text] [Related]
15. Serum galectin-3 level in systemic sclerosis.
Koca SS; Akbas F; Ozgen M; Yolbas S; Ilhan N; Gundogdu B; Isik A
Clin Rheumatol; 2014 Feb; 33(2):215-20. PubMed ID: 23912642
[TBL] [Abstract][Full Text] [Related]
16. Up regulated expression of fractalkine/CX3CL1 and CX3CR1 in patients with systemic sclerosis.
Hasegawa M; Sato S; Echigo T; Hamaguchi Y; Yasui M; Takehara K
Ann Rheum Dis; 2005 Jan; 64(1):21-8. PubMed ID: 15608300
[TBL] [Abstract][Full Text] [Related]
17. Metabolic syndrome and adipokine levels in systemic lupus erythematosus and systemic sclerosis.
Gigante A; Iannazzo F; Navarini L; Sgariglia MC; Margiotta DPE; Vaiarello V; Foti F; Afeltra A; Cianci R; Rosato E
Clin Rheumatol; 2021 Oct; 40(10):4253-4258. PubMed ID: 33839992
[TBL] [Abstract][Full Text] [Related]
18. Circulating galectin-1 concentrations in systemic sclerosis: potential contribution to digital vasculopathy.
Yanaba K; Asano Y; Akamata K; Noda S; Aozasa N; Taniguchi T; Takahashi T; Toyama T; Ichimura Y; Sumida H; Kuwano Y; Miyazaki M; Sato S
Int J Rheum Dis; 2016 Jun; 19(6):622-7. PubMed ID: 24517166
[TBL] [Abstract][Full Text] [Related]
19. Serum resistin is predictive marker of development of new digital ulcers in systemic sclerosis.
Pellicano C; Leodori G; Colalillo A; Navarini L; Gigante A; Rosato E
Clin Exp Med; 2022 Aug; 22(3):421-426. PubMed ID: 34462844
[TBL] [Abstract][Full Text] [Related]
20. Resistin: a possible biomarker of organ involvement in systemic sclerosis patients?
Sawicka K; Michalska-Jakubus M; Kowal M; Potembska E; Krasowska D
Clin Exp Rheumatol; 2017; 35 Suppl 106(4):144-150. PubMed ID: 28980898
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
